Nuwellis Pediatric Segment Reaches 50% of Total U.S. Revenue in 2025

Nuwellis (NUWE) reported that its pediatric segment contributed approximately 50% of its total U.S. revenue in 2025, supported by an operational network of 47 medical centers. Despite this strategic milestone, the company's stock has faced significant pressure, experiencing a 97% decline over the past year. While Nuwellis maintains a robust gross profit margin of 62%, the firm remains currently unprofitable as it continues to scale its specialized healthcare solutions. Looking forward, analysts forecast a revenue growth of 9% for the 2026 fiscal year. Furthermore, data from InvestingPro suggests that the stock may currently be undervalued relative to its intrinsic potential. This combination of high-margin specialized growth and current market volatility presents a complex valuation outlook for investors.